Business Wire

Neustar Unveils UltraBot Protect to Deliver More Visibility Into and Control Over Web Application Traffic

Share

Neustar Inc., a global information services and technology company and leader in identity resolution, today introduced UltraBot Protect to provide users with more visibility into, and control over, their application layer traffic. UltraBot Protect delivers enhanced capabilities that allow users to examine traffic patterns to determine risk, easily set rules, and block nefarious web application traffic, all through an intuitive, dynamic and comprehensive user interface or Neustar’s extensible API, both of which deliver actionable data and insights to better manage incoming traffic.

Neustar’s portfolio of application security products, which also includes UltraDDoS Protect and UltraWAF, utilises deep insights of network traffic to ensure users’ digital networks are secure across all touchpoints. Newly augmented with the robust bot management capabilities of UltraBot Protect, it becomes even more powerful.

“As digital initiatives accelerated during the pandemic, companies invested in application-rich environments that have inadvertently created opportunity for bad actors,” said Michael Kaczmarek, vice president of product management for Neustar’s Security Solutions business. “Cybercriminals are exploiting security gaps – such as through automated scanning that provides broad coverage searching for certain vulnerabilities in applications and infrastructure solutions – to find and attack new targets, especially in industries like gaming, retail and e-commerce, healthcare, and financial services.”

A recent Neustar International Security Council (NISC) report found that 84% of organisations invest significant time into continually modifying their web application firewalls (WAFs) to keep up with ever-growing, increasingly stealthy application-layer attacks. Even for organisations that have a highly tuned and optimised WAF on premises, the sheer volume of traffic and potential threats can exhaust resources and impact the ability to introduce greater precision to key systems.

Added Kaczmarek: “The rapid evolution of the modern enterprise has created precarious interdependencies and security gaps, making it significantly easier to exploit vulnerabilities, especially at the application layer. UltraBot Protect marries extensive bot detection capabilities with a sleek and straightforward interface that gives users a clear and complete view of the data, helping them set effective parameters in managing and blocking traffic to keep systems safe and assets protected.”

UltraBot Protect and all its features are now accessible to UltraWAF and UltraDDoS Protect customers. Features include IP reputation coverage, which involves the review of a wide range of IP categories — scanners, DOS, phishing, proxy, etc. — to examine whether a malicious IP address is the source; device fingerprint, which detects a fingerprint ID in the incoming request header and browser attributes; and bot trap, which determines whether a bot or human user is incoming based on detection traced to a specific bot trap URL. Additionally, UltraBot Protect covers the basics, such as customised block and allow lists, bot rate limits and transactions per second, as well as captcha to detect whether traffic is human or bot generated. More information about UltraBot Protect can be found at https://www.home.neustar/bot-management.

About Neustar

Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Liam Kirkham, Snr Programme Manager
Hotwire Global
liam.kirkham@hotwireglobal.com
+44 207 608 4636

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye